维布妥昔单抗联合化疗治疗III或IV期经典型霍奇金淋巴瘤(ECHELON-1):5年更新
ECHELON-1是一项国际、开放标签、随机3期试验,比较A+AVD与ABVD一线治疗III/IV期经典型霍奇金淋巴瘤。A+AVD应优先于ABVD用于该人群。
要点
- A+AVD组持续周围神经病变19% vs ABVD组9%,第二恶性肿瘤A+AVD组3% vs ABVD组4%。
核心结论
- 随访5年,A+AVD较ABVD显著且持久改善无进展生存,无论PET-2状态,安全性一致。
- 基于此,A+AVD应优先于ABVD用于既往未治疗的III或IV期经典型霍奇金淋巴瘤患者。
研究设计与样本
- 国际、开放标签、随机3期试验,在21个国家218个中心进行。
- 纳入≥18岁、ECOG体能状态≤2、既往未治疗的III或IV期经典型霍奇金淋巴瘤患者1334例,1:1随机至A+AVD组(n=664)或ABVD组(n=670)。
主要发现
- 周围神经病变持续改善或缓解:A+AVD组375/443例(85%),ABVD组245/286例(86%);持续周围神经病变A+AVD组127/662例(19%) vs ABVD组59/659例(9%)。
- 第二恶性肿瘤A+AVD组19/662例(3%) vs ABVD组29/659例(4%);活产A+AVD组75例 vs ABVD组50例。
关键数值与推荐
- ABVD方案:多柔比星25 mg/m2,博来霉素10 U/m2,长春碱6 mg/m2,达卡巴嗪375 mg/m2,每28天周期第1、15天静脉给药,最多6周期。
临床怎么用
- 对于既往未治疗的III或IV期经典型霍奇金淋巴瘤,A+AVD应优先于ABVD作为一线治疗选择。
- 治疗前应评估周围神经病变风险,治疗中监测神经毒性,尽管多数可改善或缓解,但A+AVD组持续神经病变比例较高。
局限性
- 5年分析中无进展生存率为探索性终点,且5年分析未在方案中预先设定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite advances in the treatment of Hodgkin lymphoma with the introduction of PET-adapted regimens, practical challenges prevent more widespread use of these approaches. The ECHELON-1 study assessed the safety and efficacy of front-line A+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in patients with stage III or IV classical Hodgkin lymphoma. The primary analysis showed improved modified progression-free survival with A+AVD. We present an updated analysis of ECHELON-1 at 5 years, an important landmark for this patient population. METHODS: ECHELON-1 was an international, open-label, randomised, phase 3 trial done at 218 clinical sites, including hospitals, cancer centres, and community clinics, in 21 countries. Previously untreated patients (≥18 years with an Eastern Cooperative Oncology Group performance status of ≤2) with stage III or IV classical Hodgkin lymphoma were randomly assigned (1:1) to receive A+AVD (brentuximab vedotin, 1·2 mg/kg of bodyweight, doxorubicin 25 mg/m2 of body surface area, vinblastine 6 mg/m2, and dacarbazine 375 mg/m2) or ABVD (doxorubicin 25 mg/m2, bleomycin 10 U/m2, vinblastine 6 mg/m2, and dacarbazine 375 mg/m2) intravenously on days 1 and 15 of each 28-day cycle for up to six cycles. Stratification factors included region (Americas vs Europe vs Asia) and International Prognostic Score risk group (low, intermediate, or high risk). The primary endpoint was modified progression-free survival; this 5-year update includes analysis of progression-free survival as per investigator assessment in the intention-to-treat population, which was an exploratory endpoint, although the 5-year analysis was not prespecified in the protocol. This trial is registered with ClinicalTrials.gov (NCT01712490) and EudraCT (2011-005450-60), and is ongoing. FINDINGS: Between Nov 19, 2012, and Jan 13, 2016, 1334 patients were randomly assigned to receive A+AVD (n=664) or ABVD (n=670). At a median follow-up of 60·9 months (IQR 52·2-67·3), 5-year progression-free survival was 82·2% (95% CI 79·0-85·0) with A+AVD and 75·3% (71·7-78·5) with ABVD (hazard ratio [HR] 0·68 [95% CI 0·53-0·87]; p=0·0017). Among PET-2-negative patients, 5-year progression-free survival was higher with A+AVD than with ABVD (84·9% [95% CI 81·7-87·6] vs 78·9% [75·2-82·1]; HR 0·66 [95% CI 0·50-0·88]; p=0·0035). 5-year progression-free survival for PET-2-positive patients was 60·6% (95% CI 45·0-73·1) with A+AVD versus 45·9% (32·7-58·2) with ABVD (HR 0·70 [95% CI 0·39-1·26]; p=0·23). Peripheral neuropathy continued to improve or resolve over time with both A+AVD (375 [85%] of 443 patients) and ABVD (245 [86%] of 286 patients); more patients had ongoing peripheral neuropathy in the A+AVD group (127 [19%] of 662) than in the ABVD group (59 [9%] of 659). Fewer secondary malignancies were reported with A+AVD (19 [3%] of 662) than with ABVD (29 [4%] of 659). More livebirths were reported in the A+AVD group (n=75) than in the ABVD group (n=50). INTERPRETATION: With 5 years of follow-up, A+AVD showed robust and durable improvement in progression-free survival versus ABVD, regardless of PET-2 status, and a consistent safety profile. On the basis of these findings, A+AVD should be preferred over ABVD for patients with previously untreated stage III or IV classical Hodgkin lymphoma. FUNDING: Millennium Pharmaceuticals (a wholly owned subsidiary of Takeda Pharmaceutical Company), and Seagen.
引用
- Straus DJ, Długosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021. PMID: 34048680. doi:10.1016/S2352-3026(21)00102-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。